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Abstract
Background—Trastuzumab (TZB) is an established therapy for HER2 positive breast cancer. 
The use of TZB is commonly associated with cardiotoxicity manifesting as asymptomatic 
decrease in left ventricular ejection fraction (LVEF) or overt heart failure. Several studies 
demonstrated favorable effects of angiotensin converting enzyme (ACE) inhibitors and beta 
blockers (BB) in the prevention of chemotherapy-induced cardiotoxicity. We hypothesize that 
patients, randomized to receive an ACE inhibitor or a beta-blocker during trastuzumab therapy for 
breast cancer, will maintain a higher LVEF than patients randomized to placebo.
Methods and Results—We designed a prospective, multicenter, randomized, phase II placebo-
controlled clinical trial to evaluate the effects of an ACE inhibitor (lisinopril) and a β-blocker 
(carvedilol phosphate-extended release) on cardiotoxicity in patients with breast cancer who are 
receiving adjuvant or neoadjuvant TZB therapy. The primary objectives include 1) comparison of 
incidence of cardiotoxicity and 2) comparison of LVEF as a continuous variable in between the 
arms. Cardiotoxicity was defined as an absolute decrease in LVEF from baseline of ≥ 10% at 
follow-up or an absolute decrease of ≥ 5% in LVEF from baseline for individuals with < 50% 
LVEF at follow-up.
The target accrual is 468 participants, representing patients both with and without anthracycline 
exposure. The enrollment is completed. The trial is co-sponsored by University of South Florida 
and National Cancer Institute. The LVEF is being evaluated by echocardiography or multigated 
acquisition scan.
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Conclusion—If we can demonstrate that the use of an ACE inhibitor or a BB can reduce the 
degree of TZB-induced cardiotoxicity it is hoped that patients will receive complete and 
uninterrupted TZB therapy for breast cancer without compromising cardiac function.
Clinical trial registration—SCUSF 0806 NCT01009918 (url https://clinicaltrials.gov/ct2/show/
NCT01009918).
Keywords
heart failure; chemotherapy-induced cardiotoxicity; cardio-oncology
Introduction
Human Epidermal Growth Factor receptor type 2 (HER2) is a type of transmembrane 
tyrosine kinase receptor that normally regulates cell growth and survival, as well as 
adhesion, migration, differentiation, and other cellular responses. It is overexpressed in 20–
30% of invasive breast carcinomas. HER2 positivity conveys a poor prognosis and decreased 
overall survival as well as an altered response to anthracycline chemotherapeutic regimens. 
Trastuzumab (Herceptin; Genentech, Inc.) is a recombinant humanized monoclonal antibody 
that binds to the extracellular domain of the HER2 receptor. Use of trastuzumab (TZB) in 
HER2 positive breast cancer became the greatest breakthrough therapy which reduces 
mortality and dramatically improves disease-free survival. Pooled results from five 
randomized trials of adjuvant trastuzumab showed a significant reduction of mortality (p < 
0.00001), recurrence (p < 0.00001), metastases rates (p < 0.00001) and second tumors other 
than breast cancer (p = 0.007) as compared to no adjuvant TZB patients 1.
In 2001, Slamon et al reported 8.8 to 11% incidence of cardiotoxicity in patients receiving 
paclitaxel and trastuzumab comparing to 1 to 4% in those who received paclitaxel alone, and 
26 to 28% in those on trastuzumab and anthracyclines (AC) versus 6 to 9.6% on AC alone 2. 
Multiple studies have been done since and have shown similar results 3–5. Most of the cases 
of trastuzumab-induced cardiomyopathy are reversible, however, once trastuzumab is 
discontinued, oncologists are frequently hesitant to re-expose patients to this agent. 
Cardiotoxicity results in discontinuation of trastuzumab in up to 19% of patients 3. In our 
retrospective study, 19.5% of patients permanently or temporarily discontinued TZB 
secondary to cardiomyopathy 6.
There are some reports, primarily from single center studies, demonstrating the protective 
effects of angiotensine converting enzyme (ACE) inhibitors and beta blockers (BB) in 
chemotherapy-induced cardiotoxicity. Specifically, Cardinale et al. 7 reported a 100% 
prevention of AC-induced cardiomyopathy by enalapril, an ACE inhibitor. Similarly, Kalay 
et al. 8 described a highly successful use of carvedilol, a BB, for prevention of 
chemotherapy-associated cardiac toxicity. Based on these reports, as well as on our 
preliminary data 6, we hypothesized that patients randomized to receive an ACE inhibitor or 
a BB, simultaneously with initiation of TZB for HER2 positive breast cancer, would 
preserve better cardiac function than those randomized to placebo. We defined cardiotoxicity 
as decrease in LVEF of < 50% with a 5% drop from baseline, or a >10% decrease in ejection 
fraction after initiating trastuzumab.
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Methods
We designed a prospective, multicenter, randomized, phase II placebo-controlled clinical 
trial evaluating the effects of an ACE inhibitor (lisinopril) and a β-blocker (carvedilol 
phosphate-extended release) on cardiotoxicity in patients with breast cancer who are 
receiving adjuvant or neoadjuvant TZB therapy. The primary objective of this study is to 
determine if administration of lisinopril or carvedilol phosphate-ER, compared to placebo, 
will reduce the incidence of trastuzumab-induced cardiotoxicity, as measured by LVEF, in 
patients receiving adjuvant or neoadjuvant therapy for HER2 positive breast cancer. The 
secondary objectives of this study are to: 1) determine whether participants on active agent 
have fewer interruptions in TZB therapy due to cardiomyopathy, determine if treatment 
effects are consistent in anthracycline and non-anthracycline cohorts, evaluate changes in 
quality of life among the treatment groups during the study intervention, evaluate the long 
term effects of the prevention of cardiomyopathy and impact on HRQL for either or both 
active agents, and to compare the predictive value of Troponin I and BNP in the 
identification of TZB cardiotoxicity.
We chose the extended release Coreg XR, rather than generic carvedilol, because, like 
lisinopril, it is taken only once daily, and carvedilol has to be taken twice a day. A double 
blind design of the study mandated a matching pattern of use of all the drugs in the trial.
The trial is registered as SCUSF 0806 (SunCoast University of South Florida) and has a 
ClinicalTrials.gov Identifier NCT01009918. The study described was supported by Award 
Number U10CA081920 from the National Cancer Institute. Because the trial was designed 
as a “real life” study, we allowed the participating centers to select their preferred imaging 
modality. The LVEF is being evaluated by echocardiography or multigated acquisition scan, 
depending on the preferences of the clinical investigators. To provide consistency within 
centers, we required utilization of similar imaging modality throughout the follow-up, i.e. if 
the patient had an echocardiogram at the baseline, subsequent images were also obtained by 
echocardiography. Because we realize that multitude of the sites may provide inconsisted 
readings, the Echo substudy was designed, where the analysis of sample echocardiograms is 
being done by Duke core echocardiographic laboratory. Specifically, echocardiograms of all 
patients meeting the definition of cardiotoxicity per their local sites, as well as their age-
matched controls without cardiotoxicity by local readers, were sent to the core laboratory. 
The results will be reported separately from the main trial.
Definition of TZB-induced Cardiotoxicity
TZB-induced cardiotoxicity usually manifests in decrease of left ventricular ejection fraction 
(LVEF). There is no uniform definition of TZB –induced cardiotoxicity. When our trial was 
being designed, the literature demonstrated high heterogeneity in the definitions 9. Examples 
are shown in Table 1.
For SCUSF 0806 trial, we chose the definition of cardiotoxicity similar to Piccart-Gebhart et 
al.10:
1. A decrease in LVEF of ≥10% in patients whose LVEF is ≥50% or
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2. A drop in LVEF of at least 5% from baseline in patients whose LVEF decreases 
to less than 50%.
Baseline LVEF must be measured within 6 weeks of study entry.
Subjects and Randomization
Subjects meeting the inclusion/exclusion criteria and giving informed consent are 
randomized in a 1:1:1 ratio into the two treatment and control groups (lisinopril 10mg a day 
versus Coreg XR 10mg versus placebo). The target enrollment is 468 patients at 128 centers. 
The enrollment is completed. Half of the patients were exposed to anthracyclines prior to 
trastuzumab therapy, while the other half was not. In terms of randomization, once a patient 
consented to study, the site would call a toll free number and place the participant eligibility 
out sources information into the automated system that would simultaneously enroll and 
randomize the patient to study agent. The site pharmacy would receive and automated email 
with a bottle number to dispense with the patients assigned blinded study agent.
Inclusion Criteria
1.1 Women ≥ 18 years of age
1.2 HER2 positive breast cancer
1.3 Scheduled to receive adjuvant trastuzumab therapy
1.4 LVEF ≥ 50% by MUGA scan or echocardiogram, based on institutional/
clinician preference
1.5 Normal renal and hepatic function
1.6 Systolic blood pressure of > 90 mm Hg (sitting)
1.7 Pulse ≥ 60 beats/minutes
1.8 Able and willing to give informed consent
1.9 Signed HIPAA compliant research authorization to release Personal Health 
Information to the SunCoast Research Base.
Exclusion criteria
1.10 Prior treatment with trastuzumab
1.11 Current treatment with ACE inhibitors, BB or digoxin
1.12 Known cardiac history: heart failure, myocardial infarction, radiation-induced 
cardiac dysfunction, clinically significant arrthymias, etc.
1.13 Known contraindication to either ACE inhibitors or BB
1.14 History of bronchial asthma or related bronchospastic conditions
1.15 Hereditary or idiopathic angioedema
1.16 Pregnant or breast feeding
1.17 Metastatic disease
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Study Procedures and Follow-up
The study flow is summarized in Figure 1. Trastuzumab therapy was interrupted when the 
subjects met the definition of cardiotoxicity. If the patient developed heart failure during the 
study, trastuzumab was discontinued, study assignment unblinded, and further care provided 
by local cardiologist in accordance with the guidelines. Nevertheless, follow-up visits take 
place every three months, with documentation of the disease status, medical management, 
LVEF, BNP & Troponin I; as well as QOL questionnaire at month 6 and 12.
Statistical Analyses
The primary aim of this study is to determine if treatment with lisinopril or carvedilol 
phosphate ER results in reduction in incidence of trastuzumab-induced cardiotoxicity after 
52 weeks of treatment as measured by preservation of LVEF, and comparison of the LVEF 
of each treatment group with the placebo arm (where LVEF is a continuous variable). The 
study is stratified according to whether patients received an anthracycline-containing 
regimen or not to ensure balanced randomization.
The study employs a two stage analysis plan. We will first compare each active agent arm 
with the placebo arm. If a reduction effect is statistically significant in both agents (ACE and 
BB), we will examine if there is any difference between the two study agents, recognizing 
we do not have the same statistical power for this secondary analysis. If one or neither of the 
active agent arms is statistically significantly different from the placebo arm, then the 
secondary stage analysis will not be necessary. Kaplan-Meier survival curves will be 
constructed to reflect time until event rates and the logrank statistic will be used to compare 
them. Secondary end points will be addressed by using a Student-t test to compare the 
changes of LVEF as a continuous measure between the two arms (treatment arms with 
placebo) and a Pearson chi-square test will be used to compare the proportions of decreased 
LVEF in each arm. For comparisons of each treatment with placebo, we will consider one-
sided 0.025 significant levels to adjust for the multiple testing. A mixed linear model will be 
utilized to analyze the pattern of LVEF change during the course of this study using the data 
from all follow-up visits. Furthermore, a proportional hazards model will be used to control 
for potential confounders such as use of other cardiotoxic agents (i.e., AC).
Quality of life changes will be evaluated using the European Organization for research and 
Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 V 3.0 at 
baseline and at the end of treatment (end of trastuzumab therapy or week 52). The analysis 
plan will utilize a linear regression model to consider the treatment effects on these 
measurements (dependent variables) adjusted for age and other covariates to compare the 
treatment arms. The observed data will be evaluated for normality and appropriate 
transformation introduced prior to conducting the analysis. To assess the long term effect of 
the study agents, follow-up measurements will be collected at study months 18 and 24 (or 6 
and 12 months after the last dose of trastuzumab, if it was discontinued before week 52). 
This exploratory analysis will be completed to determine the long term effects on the 
prevention of cardiomyopathy and impact on QOL for either or both study agents. The 
treatment groups will be compared to using appropriate two sample tests.
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Sample Size—The sample size calculation is based on the comparisons of each treatment 
with placebo. Using a conservative incidence estimate, we hypothesize that 15% of women 
treated for breast cancer with adjuvant trastuzumab will have decreased LVEF in the placebo 
arm as compared to 5% of the women on the treatment arms. To detect a 10% difference in 
women who exhibit a decrease in LVEF by the additional medication of lisinopril or 
carvedilol, a sample size of 141 participants per arm is required to achieve 80% power for a 
one sided test at the 0.025 significance level. Assuming a 10% drop-out rate, 468 subjects 
were randomized to one of the three arms.
As possible, all statistical analyses will be based on the intent-to-treat principle. Subjects 
will be analyzed according to their randomized assignment.
Biomarkers: B-type natriuretic peptide and Troponin—B-type natriuretic peptide 
(BNP) and Troponin are the biomarkers being checked regularly while participating on 
study. The will be used in an effort try to identify patients at risk for cardiomyopathy before 
they develop symptoms and before the drop of LVEF can be appreciated by 
echocardiography or MUGA. Cardiac troponin I (TnI) may be a very reliable biomarker. In a 
single center study by Cardinale et al. 7, only 5% of patients without TnI elevation in the 
course of treatment developed cardiomyopathy. On the other hand, 62% of those with 
elevated TnI later had reduced EF. Moreover, there was less recovery of cardiac function in 
those patients who had elevated TnI. If this is confirmed in a randomized clinical trial like 
the one we are doing now, the strategy may be changed from imaging patients every three 
months which is cumbersome and costly to screening them with TnI first, and selectively 
imaging only those in whom it is abnormal. There is no data on head to head comparison on 
BNP and TnI. Receiver operating characteristic (ROC) curves will be used to determine the 
value of these biomarkers in predicting trastuzumab-induced cardiotoxicity: The null 
hypothesis is that areas under ROC (AUCROC) for the two biomarkers regarding 
identification of trastuzumab induced cardiotoxicity (primary endpoint) are equal. The 
AUCROC will be tested using Delong’s nonparametric approach, applying generalized U-
statistics to generate an estimated covariance matrix for correlated ROC curves. Due to the 
uncertainty about the treatment effect of the active drugs, this analysis will be limited to the 
placebo group only. With approximate 15% incidence rate in the placebo group, the 
proposed sample size will achieve a power greater than 80% to reject the null if the true
Safety management—Patients are monitored for adverse events attributable to study 
agent at every study visit according to the Common Terminology Criteria for Adverse 
Events (CTCAE) v4.0. All adverse events attributable to study agent were reported to the 
SunCoast CCOP Research Base staff according to FDA guidelines. The study was also 
reviewed for safety and progress by a Data Safety Monitoring Board every 6 months.
Discussion
This prospective randomized multicenter double blind placebo-controlled trial is the largest 
study to address the prevention of TZB-induced cardiotoxicity. Unlike this study, most 
similar studies addressing this important clinical issue are conducted in single centers, with 
smaller sample size and less rigorous design 7, 8.
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The incidence of cardiomyopathy reported in individual clinical trials varies widely and 
ranges from 7% 4 to 34% 11. In an overview of selected clinical trials on adjuvant breast 
cancer treatment, Ewer et al.12 reported that overt clinical heart failure developed in < 4% of 
patients, while asymptomatic decline in LVEF by 10 points was seen in ≤ 30% of patients. 
Jones et al. report adverse cardiac effects in 5 of 28(17.9%), with two of them (3.8%) 
symptomatic 13. Bhimaraj et al. 14 report cardiac dysfunction in 32%, including 14.3% 
symptomatic, in their mixed adjuvant and metastatic patients. The University of Texas M.D. 
Anderson Cancer Center (Houston, TX), observed cardiomyopathy in 28% of patients, with 
a more stringent definition of EF decline; ≥ 20% from the baseline. There was also one 
cardiac-related death (0.5%) 15. Our sample size calculation, based on the anticipated 
cardiotoxicity rate of 15%, appears to be quite realistic.
In terms of clinical course of cardiac dysfunction which is secondary to TZB, it appears to 
be mostly reversible. The MD Anderson Cancer center study, in which patients were referred 
for suspected TZB-related cardiomyopathy, LVEF decreased from 61% +/− 13% at baseline 
to 43% +/− 16% (p < 0.0001) after trastuzumab, and increased to 56% +/− 11% after the 
discontinuation of therapy 16.
Improvement in LVEF occurs after discontinuation of TZB, with cardiac medications or 
without them, and re-exposure to TZB usually does not result in further decline in 
LVEF 4, 15, 17. However, current protocols mandate discontinuation of TZB after LVEF 
becomes abnormally low (<50%), and many women with breast cancer experience 
interruptions in therapy 6. We designed our trial in an effort to prevent the development of 
TZB-related cardiac dysfunction, using the medications that were reported to provide some 
favorable effects, in a randomized, double blinded, placebo controlled population. Our 
ultimate goal is to find the way to protect the heart and to avoid interruptions in the course of 
TZB.
The trial is designed for community oncology groups rather than large institutions.
While the trial was in progress, results of two other randomized trials were published. 
Although on a smaller scale, the two groups of investigators tried to answer similar question.
In the Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research 
(MANTICORE 101-Breast) trial, with a double-blinded, placebo-controlled design, patients 
with HER2-positive breast cancer were randomly assigned to receive treatment with 
perindopril, bisoprolol, or placebo (1:1:1, with 33, 31, and 30 patients, respectively) for the 
duration of trastuzumab adjuvant therapy. After 17 cycles of trastuzumab, indexed left 
ventricular end diastolic volume increased similarly in all patients, but trastuzumab-induced 
decline in LVEF was attenuated in bisoprolol-treated patients (−1 ± 5%) relative to the 
perindopril (−3 ± 4%) and placebo (−5 ± 5%) groups (P = .001). Perindopril and bisoprolol 
use were independent predictors of maintained LVEF on multivariable analysis 18.
The second trial utilized angiotensin II antagonist candesartan for prevention of trastuzumab 
related cardiotoxicity (defined as a decline in left ventricular ejection fraction (LVEF) of 
more than 15% or a decrease below the absolute value 45%). in adjuvant setting. With a total 
of 206 participants, randomized 1:1 into candesartan or placebo, the trial demonstrated no 
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diffirence in the number of cardiac events between the groups. Moreover, candesartan did 
not affect changes in NT-proBNP and troponin values 19.
The controversial results of these two studies underscores the timeliness of our trial.
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Figure 1. 
SCUSF 0806 Flowchart
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Table 1
Definitions of TZB-induced cardiotoxicity at the time of designing the current clinical trial
Author Year N Setting Definition of cardiotoxicity
Burstein 20 2001 40 Metastatic breast cancer LVEF< 50% or decrease by 15%
Leyland-Jones 11 2003 32 Metastatic breast cancer LVEF<40% or decrease by >15%
Romond 3 2005 1159 Adjuvant LVEF< 55% or decrease by >16%
Burstein 21 2003 54 Metastatic breast cancer EF<40%
Bengala 13 2006 53 mixed EF<50%
Tan-Chiu 22 2005 850 Adjuvant EF decrease by 10% to < 55%
Piccart-Gebhart 10 2005 1677 Adjuvant EF< 50% or decrease by 10%
Venturini 5 2006 45 Metastatic breast cancer EF <45% or decrease by 20%
Guarneri 15 2006 173 Metastatic breast cancer EF < 50% or decrease by 20%
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